Image
Group 2354.png

Burden

 

Cardiovascular diseases (CVDs) are the leading cause of death globally1

17.92 million CV deaths in 20151

Image
Frame 427318568.png

Ischemic heart disease

8.92 million1

Image
Frame 427318568-1.png

Ischemic stroke

6.33 million1

Image
Frame 427318568-2.png

Peripheral artery disease

52,5001

Image
Group 2358.png

 

Ischemic heart disease and stroke ranked as the world’s leading and third leading causes of death, accounting for 84.5% of cardiovascular deaths and 28.2% of all global deaths.2

Patients with established clinical ASCVD have an increased risk of recurrent ASCVD events3

Image
Group 2367.png

UNMET NEEDS

 In the real world, too many patients are still at risk 4

Image
Group 2357.png

*2019 risk-based LDL-C goals: low risk: <3.0 mmol/L moderate risk: <2.6 mmol/L; high risk: <1.8 mmol/L; very-high risk: <1.4 mmol/L .4

Real-world evidence from DA VINCI shows:

Despite treatment intensification, most patients do not get to goal4

2019 ESC/EAS risk-based LDL-C goal attainment4

Image
Group 2345.png

EDA Approval No: WF0424OA5708/042026 EDA Invalidation Date:06/04/2027

References

  1. Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, Ahmed M, Aksut B, Alam T, Alam K, Alla F. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. Journal of the American college of cardiology. 2017 Jul 4;70(1):1-25.

  2. Barquera S, Pedroza-Tobías A, Medina C, Hernández-Barrera L, Bibbins-Domingo K, Lozano R, Moran AE. Global overview of the epidemiology of atherosclerotic cardiovascular disease. Archives of medical research. 2015 Jul 1;46(5):328-38.

  3. Rosenblit PD. Extreme atherosclerotic cardiovascular disease (ASCVD) risk recognition. Current diabetes reports. 2019 Aug;19(8):61.

  4. Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, Murphy J, Banach M, De Servi S, Gaita D, Gouni-Berthold I. EU-Wi de Cross-Section al Obser v at ion al Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. European journal of preventive cardiology. 2021 Nov 1;28(11):1279-89a scientific statement from the American Heart Association. Circulation. 2019 Mar 26;139(13):e603-34.

Adverse Events Reporting

We encourage using the following Electronic reporting tool for reporting into the safety database directly:
If the electronic reporting tool is not working - please use the following: https://www.report.novartis.com
1 - Generic Mailbox: [email protected]
2 - CISCO: +20 2 2 2861000: Press 3 for Adverse Events Reporting